CIK 0001503802
- Non-accelerated filer
- Smaller reporting company
Karyopharm Therapeutics Inc.
Sign in to watch- Tickers
- KPTI KPTIQ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 263931704
- Phone
- +1 617-658-0600
- Business address
- 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459
Securities
- KPTI Common stock Nasdaq
- KPTIQ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,135
- in 3 filings
Net −$2,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-15 | Frenkel Ran EVP, Chief Dev. Officer | Exercise or conversion | +9,675 | 49,013 | ||
| 2021-02-15 | Frenkel Ran EVP, Chief Dev. Officer | Exercise or conversion · Restricted Stock Units | −9,675 | 19,350 | ||
| 2021-02-15 | Shacham Sharon President & CSO | Exercise or conversion | +21,800 | 785,947 | ||
| 2021-02-15 | Shacham Sharon President & CSO | Exercise or conversion | +21,800 | 584,621 | ||
| 2021-02-15 | Shacham Sharon President & CSO | Exercise or conversion · Restricted Stock Units | −21,800 | 43,600 | ||
| 2021-02-15 | Shacham Sharon President & CSO | Exercise or conversion · Restricted Stock Units | −21,800 | 43,600 | ||
| 2021-02-15 | Kauffman Michael Chief Executive Officer | Exercise or conversion | +21,800 | 584,621 | ||
| 2021-02-15 | Kauffman Michael Chief Executive Officer | Exercise or conversion | +21,800 | 785,947 | ||
| 2021-02-15 | Kauffman Michael Chief Executive Officer | Exercise or conversion · Restricted Stock Units | −21,800 | 43,600 | ||
| 2021-02-15 | Kauffman Michael Chief Executive Officer | Exercise or conversion · Restricted Stock Units | −21,800 | 43,600 | ||
| 2021-02-11 | Lewis Tanya EVP, Chief Reg. Affairs | Sale | −2,046 | $15.52 | $32K | 4,143 |
| 2021-02-11 | Shah Jatin EVP, Chief Medical Officer | Sale | −1,748 | $15.52 | $27K | 48,127 |
| 2021-02-11 | Frenkel Ran EVP, Chief Dev. Officer | Sale | −2,046 | $15.52 | $32K | 39,338 |
| 2021-02-11 | Mason Michael SVP, CFO & Treasurer | Sale | −2,858 | $15.52 | $44K | 5,292 |
| 2021-02-11 | Shacham Sharon President & CSO | Sale | −6,642 | $15.52 | $103K | 764,147 |
| 2021-02-11 | Shacham Sharon President & CSO | Sale | −6,601 | $15.52 | $102K | 562,821 |
| 2021-02-11 | Kauffman Michael Chief Executive Officer | Sale | −6,601 | $15.52 | $102K | 562,821 |
| 2021-02-11 | Kauffman Michael Chief Executive Officer | Sale | −6,642 | $15.52 | $103K | 764,147 |
| 2021-02-05 | Shah Jatin EVP, Chief Medical Officer | Exercise or conversion | +5,650 | 49,875 | ||
| 2021-02-05 | Shah Jatin EVP, Chief Medical Officer | Exercise or conversion · Restricted Stock Units | −5,650 | 16,950 |
Page 18 of 29 · 570 trades